Roche Holding AG — Zelboraf EMA EPAR public assessment report (EMEA/H/C/002409, 2012)
Roche Holding AG · 2012 · EMA EPAR public assessment report · company profile →
Report summary
This EMA EPAR summarizes the assessment of Zelboraf (vemurafenib) for BRAF V600 mutation-positive unresectable or metastatic melanoma. Preclinical studies confirmed its selective BRAF inhibition and evaluated safety, pharmacokinetics, and toxicology, including genotoxicity and phototoxicity. Clinical trials, notably the Phase III BRIM 3 study, demonstrated vemurafenib's superior efficacy over dacarbazine, significantly improving overall and progression-free survival. However, vemurafenib's safety profile revealed common adverse events, particularly skin-related issues like cutaneous squamous cell carcinoma (cuSCC), QT prolongation, and various dermatologic reactions. The risk management plan addresses these identified and potential risks, outlining pharmacovigilance and minimization strategies, including patient education and dose modifications. Despite safety concerns, the CHMP concluded a positive benefit-risk balance, recommending marketing authorization due to its significant efficacy in this patient population.
Key findings — cited to the page
| Grade 4 AEs (vemurafenib) | 4 % | · p.70 |
| Grade 3+ neutropenia (dacarbazine) | 9 % | · p.70 |
| Grade 3+ decreased neutrophil count (dacarbazine) | 4 % | · p.70 |
| patients with Grade 2/moderate AEs (dacarbazine) | 51 % | · p.70 |
| Grade 3+ SCC of skin (vemurafenib) | 11 % | · p.70 |
| Grade 3+ rash (vemurafenib) | 8 % | · p.70 |
| patients with Grade 1/mild AEs (vemurafenib) | 94 % | · p.70 |
| patients with Grade 3 or above AEs (vemurafenib) | 50 % | · p.70 |
| patients with Grade 1/mild AEs (dacarbazine) | 78 % | · p.70 |
| patients with Grade 2/moderate AEs (vemurafenib) | 78 % | · p.70 |
| patients with Grade 3 or above AEs (dacarbazine) | 30 % | · p.70 |
| Grade 4 AEs (dacarbazine) | 8 % | · p.70 |
Source: Roche Holding AG ↗ · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →